Gilead Sciences Inc. closed 11.48% below its 52-week high of $119.96, which the company reached on March 10th.

Gilead Sciences chairman and CEO Daniel O’Day joins 'Squawk Box' to discuss the FDA approval of the company's HIV prevention ...

The U.S. has approved the world's only twice-a-year shot to prevent HIV, the first step in an anticipated global rollout that ...

Big Pharma delivers another life-saving medical advance, and another demonstration of the folly of price controls.

**NM signifies a non meaningful value. A dash signifies the data is not available.

Amgen said Monday it's expanding development plans for its weight-loss drug, MariTide, to include cardiovascular conditions ...